Jim Wilson's team hands Precision Bio a big proxy win for its PCSK9 gene editing tech with 3-year monkey data
James Wilson and his gene editing team at UPenn have published a new paper into a one-time PCSK9 therapy, one that Precision Biosciences hopes can turn up the heat on its competitors at Verve.
Using Precision’s proprietary ARCUS gene editing platform, Wilson was able to demonstrate that PCSK9 protein and LDL cholesterol reductions could be sustained in monkeys for at least three years after treatment, Precision announced Friday. Researchers administered the therapy to 10 monkeys back in 2017 and reported reductions of up to 85% in PCSK9 protein levels and a 56% reduction of LDL cholesterol levels.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
